AbbVie Inc.Long
ABBV an Entry Point into the Wild World of Biotech
Biotechnology and pharmaceutical companies have been quickly cycling through overbought and oversold. The problem has been so problematic that Sorrento Therapeutics had to specifically claim they were not a “pump and dump” scheme. Any whisper of a "cure" for Covid-19 has investors rushing to the entrance and quickly fleeing after results are what they had expected (an image of people rushing toward the exit and getting stuck in door comes to my mind). People who know the biotech sector have been cautiously watching the spectacle and trying to avoid getting trampled in a stampede. To be clear: your average investor is getting burned in the vaccine-hunt game.
AbbVie "ABBV" is (and has been) a reliable pharmaceutical and biotechnology company for some time. The company is known for its generous dividend – previously at a yield of 5.20%. The company has a robust balance sheet with a Quick Ratio of 3.03 and a Current Ratio of 3.14. In the world of biotech, research and development is everything. ABBV pipeline is stacked with potential drug candidates many of which are in Phase 3 of development according to AbbVie’s investor relations brochure.
From a technical analysis standpoint, the moving averages appear to be moving toward a positive crossover – EMA10 = 91.00, EMA20 = 90.88 EMA25 = 90.87. The stock does not look overbought or oversold according to the Stoch RSI and Money Flow Indicator. However, the MACD indicator shows that there may be a further swing downward before moving into positive territory. Finally, the linear regression model is one of the few biotechnology companies that is not inverse or appears caught in a sideway pattern.
LONG ABBV purchased today (06-02-2020) @ 90.86.
AbbVie "ABBV" is (and has been) a reliable pharmaceutical and biotechnology company for some time. The company is known for its generous dividend – previously at a yield of 5.20%. The company has a robust balance sheet with a Quick Ratio of 3.03 and a Current Ratio of 3.14. In the world of biotech, research and development is everything. ABBV pipeline is stacked with potential drug candidates many of which are in Phase 3 of development according to AbbVie’s investor relations brochure.
From a technical analysis standpoint, the moving averages appear to be moving toward a positive crossover – EMA10 = 91.00, EMA20 = 90.88 EMA25 = 90.87. The stock does not look overbought or oversold according to the Stoch RSI and Money Flow Indicator. However, the MACD indicator shows that there may be a further swing downward before moving into positive territory. Finally, the linear regression model is one of the few biotechnology companies that is not inverse or appears caught in a sideway pattern.
LONG ABBV purchased today (06-02-2020) @ 90.86.
Wyłączenie odpowiedzialności
Informacje i publikacje przygotowane przez TradingView lub jego użytkowników, prezentowane na tej stronie, nie stanowią rekomendacji ani porad handlowych, inwestycyjnych i finansowych i nie powinny być w ten sposób traktowane ani wykorzystywane. Więcej informacji na ten temat znajdziesz w naszym Regulaminie.